Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: Role of STAT3 signaling

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 2, 2010, Pages

  Merke, Matthias J ^a,b   Liu, Lijuan ^a   Cao, Zhiping ^a   Packwood, William ^a   Young, Jennifer ^b   Alkayed, Nabil J ^b   Van Winkle, Donna M ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

14,15 EET; Eicosanoid; N adamantanyl N dodecanoic acid urea; Oxygen and glucose deprivation; Reoxygenation and glucose repletion

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 14,15 EPOXYEICOSA 5 ENOIC ACID; ARACHIDIC ACID; ARGININE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; GLUTAMINE; JANUS KINASE 2; LAURIC ACID; N ADAMANTANYL N' DODECANOIC ACID UREA; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EPHX2 GENE; GENE; GENE DELETION; HEART INFARCTION SIZE; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; KNOCKOUT MOUSE; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REPERFUSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EPOXIDE HYDROLASES; JANUS KINASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 74949142180     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00533.2009     Document Type: Article

References (34)

1. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, Schulz R. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 102: 131-135, 2008.
2. Bolli R. The late phase of preconditioning. Circ Res 87: 972-983, 2000.
3. Burdon KP, Lehtinen AB, Langefeld CD, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW. Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study. Diab Vasc Dis Res 5: 128-134, 2008.
4. Cao Z, Liu L, Packwood W, Merkel M, Hurn PD, Van Winkle DM. Sex differences in the mechanism of Met5-enkephalin-induced cardioprotection: role of PI3K/Akt. Am J Physiol Heart Circ Physiol 294: H302-H310, 2008.
5. Cheranov SY, Karpurapu M, Wang D, Zhang B, Venema RC, Rao GN. An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood 111: 5581-5591, 2008.
6. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, Bolli R. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 64: 61-71, 2004.
7. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109: 335-339, 2004.
8. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 14: 2829-2837, 2005.
9. Fuglesteg BN, Suleman N, Tiron C, Kanhema T, Lacerda L, Andreasen TV, Sack MN, Jonassen AK, Mjos OD, Opie LH, Lecour S. Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. Basic Res Cardiol 103: 444-453, 2008.
10. Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL. Regulating RISK: a role for JAK-STAT signaling in postconditioning? Am J Physiol Heart Circ Physiol 295: H1649-H1656, 2008.
11. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 291: H827-H834, 2006.
12. Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, Campbell WB, Nithipatikom K. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol 294: H2838-H2844, 2008.
13. Gross GJ, Hsu A, Falck JR, Nithipatikom K. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol 42: 687-691, 2007.
14. Gschwendtner A, Ripke S, Freilinger T, Lichtner P, Muller-Myhsok B, Wichmann HE, Meitinger T, Dichgans M. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans. Stroke 39: 1593-1596, 2008.
15. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, mitochondria. Circulation 118: 1915-1919, 2008.
16. Huffman LC, Koch SE, Butler KL. Coronary effluent from a preconditioned heart activates the JAK-STAT pathway and induces cardioprotection in a donor heart. Am J Physiol Heart Circ Physiol 294: H257-H262, 2008.
17. Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF, Alkayed NJ. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J Neurosci 27: 4642-4649, 2007.
18. Ca channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 290: H491-H499, 2006.
19. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15: 1640-1649, 2006.
20. Liu M, Hurn PD, Alkayed NJ. Cytochrome P450 in neurological disease. Curr Drug Metab 5: 225-234, 2004.
21. Merkel MJ, Liu L, Cao Z, Packwood W, Hurn PD, Van Winkle DM. Estradiol abolishes reduction in cell death by the opioid agonist Met5-enkephalin after oxygen glucose deprivation in isolated cardiomyocytes from both sexes. Am J Physiol Heart Circ Physiol 295: H409-H415, 2008.
22. Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff JJ, Alkayed NJ, Van Winkle DM. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol 295: H2028-H2034, 2008.
23. Murphy E, Glasgow W, Fralix T, Steenbergen C. Role of lipoxygenase metabolites in ischemic preconditioning. Circ Res 76: 457-467, 1995.
24. Nithipatikom K, Moore JM, Isbell MA, Falck JR, Gross GJ. Epoxyeicosatrienoic acids in cardioprotection: ischemic vs. reperfusion injury. Am J Physiol Heart Circ Physiol 291: H537-H542, 2006.
25. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279, 1999.
26. Patel HH, Hsu AK, Gross GJ. COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat. Life Sci 75: 129-140, 2004.
27. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DF. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 64: 482-490, 2003.
28. Seubert JM, Sinal CJ, Graves J, Degraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, Hammock BD, Falck JR, Roberts H, Rockman HA, Murphy E, Zeldin DC. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99: 442-450, 2006.
29. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/ reperfusion injury. Prostaglandins Other Lipid Mediat 82: 50-59, 2007.
30. Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ. Cardiomyocyte DNA synthesis and binucleation during murine development. Am J Physiol Heart Circ Physiol 271: H2183-H2189, 1996.
31. Srivastava PK, Sharma VK, Kalonia DS, Grant DF. Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch Biochem Biophys 427: 164-169, 2004.
32. Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW, Zeldin DC. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 314: 522-532, 2005.
33. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, Moh A, Moghaddas S, Chen Q, Bobbili S, Cichy J, Dulak J, Baker DP, Wolfman A, Stuehr D, Hassan MO, Fu XY, Avadhani N, Drake JI, Fawcett P, Lesnefsky EJ, Larner AC. Function of mitochondrial Stat3 in cellular respiration. Science 323: 793-797, 2009.
34. Wei Q, Doris PA, Pollizotto MV, Boerwinkle E, Jacobs DR, Jr, Siscovick DS, Fornage M. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 190: 26-34, 2007.